Given that Akt1 inhibition promotes the activation of EGFR in breast cancer cells, we further examined whether the inhibitor of EGFR tyrosine kinase Gefitinib could suppress breast cancer metastasis induced by Akt1 inhibitor. Here, EGFR is linked to breast cancer.